Compositions and methods for treatment of cardiac diseases

A plurality of microRNA (miR) antagonists, comprising one or more miR-99a-5p antagonists, one or more miR-100-5p antagonists, one or more miR-Let-7a-5p antagonists, and one or more miR-Let-7c-5p antagonists, wherein:

• (a) at least one of the one or more miR-99a-5p antagonists comprises (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs:
• 47, 48, 50, 52, and 54, and (ii) a chemical modification selected from the group consisting of a modified internucleoside linkage, a modified nucleotide, a modified sugar moiety, and combinations thereof;
• (b) at least one of the one or more miR-100-5p antagonists comprises (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs:
• 46, 49, 51, 53, and 55, and (ii) a chemical modification selected from the group consisting of a modified internucleoside linkage, a modified nucleotide, a modified sugar moiety, and combinations thereof;
• (c) at least one of the one or more Let-7a-5p antagonists comprises (i) a nucleotide sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs:
• 37, 39, and 40-45, and (ii) a chemical modification selected from the group consisting of a modified internucleoside linkage, a modified nucleotide, a modified sugar moiety, and combinations thereof;
• or
• (d) at least one of the one or more Let-7c-5p antagonists comprises (i) a nucleotide sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs:
• 36, 38, and 40-45, and (ii) a chemical modification selected from the group consisting of a modified internucleoside linkage, a modified nucleotide, a modified sugar moiety, and combinations thereof.